TY - JOUR
T1 - Reversible pulmonary toxicity due to lenalidomide
AU - Coates, Stephanie
AU - Barker, Alan
AU - Spurgeon, Stephen
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/6
Y1 - 2012/6
N2 - Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of myelodysplastic syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma. Pulmonary toxicity with thalidomide is a recognized potential complication; however, there have only been two case reports in the literature of lenalidomide-associated pulmonary toxicity. In this case, we describe a patient who developed profound dyspnea, decreased exercisetolerance, and new ground-glass opacities with reticulation, consistent with a nonspecific interstitial pneumonia pattern. Clinical suspicion for pulmonary drug toxicity was high and lenalidomide was discontinued. Within 2 weeks of stopping lenalidomide, the patient had significant improvement in dyspnea and interstitial changes on CT were resolving. After 8 weeks, there was complete resolution of symptoms. Lenalidomide-induced pulmonary toxicity is significantly debilitating but, to date, it appears to be reversible with discontinuation of the medication.
AB - Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of myelodysplastic syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma. Pulmonary toxicity with thalidomide is a recognized potential complication; however, there have only been two case reports in the literature of lenalidomide-associated pulmonary toxicity. In this case, we describe a patient who developed profound dyspnea, decreased exercisetolerance, and new ground-glass opacities with reticulation, consistent with a nonspecific interstitial pneumonia pattern. Clinical suspicion for pulmonary drug toxicity was high and lenalidomide was discontinued. Within 2 weeks of stopping lenalidomide, the patient had significant improvement in dyspnea and interstitial changes on CT were resolving. After 8 weeks, there was complete resolution of symptoms. Lenalidomide-induced pulmonary toxicity is significantly debilitating but, to date, it appears to be reversible with discontinuation of the medication.
KW - Lenalidomide
KW - drug toxicity
KW - pulmonary toxicity
UR - http://www.scopus.com/inward/record.url?scp=84871816198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871816198&partnerID=8YFLogxK
U2 - 10.1177/1078155211408374
DO - 10.1177/1078155211408374
M3 - Article
C2 - 21742815
AN - SCOPUS:84871816198
SN - 1078-1552
VL - 18
SP - 284
EP - 286
JO - Journal of Oncology Pharmacy Practice
JF - Journal of Oncology Pharmacy Practice
IS - 2
ER -